08:37 AM EDT, 06/20/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Thursday that its investigational therapy suvecaltamide did not meet its primary endpoint in a phase 2b trial evaluating its efficacy and safety in adult patients with essential tremor.

The company said Suvecaltamide did not achieve statistical significance in reducing certain tremor characteristics.

Jazz said it is waiting for the results of a suvecaltamide trial in Parkinson's disease tremor, which are expected to come out in Q1 next year, to determine the next steps for the drug's program.

Shares of the company were down 4.8% in recent Thursday premarket activity.

Price: 109.51, Change: -3.17, Percent Change: -2.81